Genexine Inc (095700) fair value: what the stock is really worth
As of Nov 18, 2026: fair value (intrinsic value) of Genexine Inc stock KRW 1,699, price KRW 1,806, that is 6.0% below the price, quality 37 out of 100. Rating: fairly valued. The value is an estimate: none of our valuation models currently carries, it draws on revenue and assets compared with similar companies. Updated daily.
- Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free
Genexine Inc
095700 · KQThe stock is already about fairly priced, weak company and falling price: meets none of the 3 rules.
What runs behind every stock
69 individual criteria per stock, every one traceable See the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 16, 2026.
How to read this chart
60‑month range 1,806 KRW – 67,821 KRW · fair‑value band 1,274 KRW – 2,123 KRW · the 1,806 KRW price screens above the 1,699 KRW fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 16, 2026.
Every Wednesday you see whether Genexine is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Company profile
Genexine, Inc., together with its subsidiaries, operates as a biotechnology company that focuses on the development and commercialization of immunotherapies in South Korea and internationally.
Show moreShow less
The company develops its products through its hybrid Fc platform, a proprietary technology designed to develop long-acting protein drugs; and the DNA vaccine platform that is used to elicit immune responses in the human body to fight viral infection and cancer cells.
Its product pipeline includes GX-H9, which is in Phase II and III clinical trials for the treatment of adult and pediatric growth hormone deficiency; GX-E4 that is in Phase III clinical trials for the treatment of anemia; GX-G3, which is in Phase II clinical trials to treat neutropenia; GX-I7, a product candidate in Phase I and II clinical trials to treat solid tumors, lymphopenia, and COVID-19; GX-P1, which is in Phase I clinical trials for the treatment of autoimmune diseases and transplantation; and GX-G6 that is in Phase II clinical trials for the treatment of diabetes.
The company is also developing GX-188E that is in Phase II clinical trials for the treatment of cervical cancer, and head and neck cancer. The company was formerly known as Genexine Co., Ltd. and changed its name to Genexine, Inc. in March 2013.
Genexine, Inc. was founded in 1999 and is headquartered in Seoul, South Korea.
Stock analysis
Genexine Inc (095700) currently trades at 1,806 KRW, while our estimate is 1,699 KRW, so the stock looks roughly fairly valued today (gap 6.4%).
Show more
Valuation
None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.
Scenario range: 1,274 KRW (bear) to 2,123 KRW (bull), the price of 1,806 KRW sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 37/100 (below-average quality), in the Healthcare sector.
Weak Growth: Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.
Genexine Inc reported revenue of 4.6B KRW in FY2025 versus 36.8B KRW in FY2021, a compound −40.6%/yr. Reported net income was −27.2B KRW in FY2025.
Key figures
Market cap 82.1B KRW (≈ $61.6M) Micro · P/S ratio 17.6 · EPS (TTM) −1,199 KRW · Return on equity −17.3% · Return on assets (EBIT) −8.7% (5-year average) · Operating margin −610% · Revenue (TTM) 5.8B KRW · Revenue growth (YoY) +200%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 12 out of 100 (medium confidence).
What moves the price
The share trades about 75% below its 52-week high and at its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −6% fair-value upside, at −6%, 095700 screens cheaper than that median.
Fair Value
Quality Score breakdown
It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.
Revenue & earnings trend
Watch 095700, get fair value alerts →
Compare Genexine Inc with another stock
Price, fair value, quality and upside side by side.
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 850 stocks
Valuation Multiplesvs Biotechnology median · lower = cheaper
Strength profile in five axes (Snowflake)
Context: sector, industry, market
- Is the Health Care sector expensive or cheap?
- P/E, EV/EBITDA and margins by industry (reference tables)
- Net margin by industry
- P/B ratio by industry
- Piotroski F-Score screener with fair value
- Undervalued stocks: South Korean Stocks
- Valuation of the Korea market
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
Similar stocks
10 more Biotechnology stocks, each showing price versus our Fair Value estimate.
| Stock | Price | Fair Value | vs Fair Value | Compare |
|---|---|---|---|---|
| Regeneron Pharmaceuticals, Inc REGN | $957.76 | $1,275 | +33% | vs 095700 |
| Samsung Biologics Co 207940 | 1,366,000 KRW | 1,552,100 KRW | +14% | vs 095700 |
| Vertex Pharmaceuticals Incorporated VRTX | $534.20 | $587.62 | +10% | vs 095700 |
| argenx SE ARGX | $947.52 | $908.40 | −4% | vs 095700 |
| CSL Limited CSL | A$199.38 | A$186.49 | −6% | vs 095700 |
| Moderna, Inc MRNA | $206.80 | $135.64 | −34% | vs 095700 |
| BeOne Medicines AG 6160 | HK$244.80 | HK$152.92 | −38% | vs 095700 |
| Revolution Medicines, Inc RVMD | $162.69 | $88.78 | −45% | vs 095700 |
| Celltrion, Inc 068270 | 207,500 KRW | 74,945 KRW | −64% | vs 095700 |
| Royalty Pharma plc RPRX | $68.68 | $19.01 | −72% | vs 095700 |
Explore undervalued stocks
More undervalued Healthcare stocks →
Try a ready-made strategy
Pick a strategy and jump into the live analysis with that exact screen applied.
Discover tools
Frequently asked questions
Is Genexine Inc (095700) overvalued or undervalued?
What is the fair value of 095700?
What is the quality score of 095700?
What is the price target for Genexine Inc (095700)?
What is the Genexine Inc stock forecast for 2026?
What is the revenue of Genexine Inc (095700)?
What is the intrinsic value of Genexine Inc (095700)?
Is Genexine Inc stock overvalued or undervalued in 2026?
Is fair value the same as the market price of 095700?
How much is Genexine Inc worth?
What do the bullish and bearish scenarios say about 095700?
How solid is the balance sheet of Genexine Inc (095700)?
How far is 095700 from its 52-week high?
Which stocks are comparable to Genexine Inc?
Is Genexine Inc stock attractive at the current price?
Is it still worth investing in stocks now?
What is the share price of Genexine Inc (095700)?
What should I pay attention to with Genexine Inc right now?
Key figures of Genexine Inc
How large is the market capitalisation of Genexine Inc (095700)?
What is the P/S ratio of Genexine Inc (095700)?
What are the earnings per share of Genexine Inc (095700)?
What is the return on equity of Genexine Inc (095700)?
What is the EBIT return on assets of Genexine Inc (095700)?
What is the operating margin of Genexine Inc (095700)?
How fast is revenue growing at Genexine Inc (095700)?
How much free cash flow does Genexine Inc (095700) generate?
How much net debt does Genexine Inc (095700) carry?
Watch Genexine Inc in the live analysis
One click puts Genexine Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Watch for free →Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.